OSE Immunotherapeutics OSE

PAR: OSE | ISIN: FR0012127173 10:55

3,720 EUR (-1,06%)

(-1,06%) 10:55

Toon enkel gratis nieuws

15 maart 2021 · OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer · Persbericht

11 maart 2021 · OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual meeting · Persbericht

23 februari 2021 · OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference · Persbericht

17 februari 2021 · OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011 · Persbericht

15 februari 2021 · OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank · Persbericht

28 januari 2021 · OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics · Persbericht

25 januari 2021 · OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011 · Persbericht

5 januari 2021 · OSE Immunotherapeutics Presentation at H.C. Wainwright BIOCONNECT 2021 Virtual Conference · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe